Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 803

1.

Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.

An G.

J Clin Pharmacol. 2019 Dec 2. doi: 10.1002/jcph.1545. [Epub ahead of print] Review.

PMID:
31793004
2.

[Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer].

Koutake Y, Tsurusaki Y, Fujita T, Inoue D, Hanada K, Nakagawa Y.

Gan To Kagaku Ryoho. 2019 Nov;46(11):1721-1725. Japanese.

PMID:
31748481
3.

A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.

Sohn BS, Jeong JH, Ahn JH, Jung KH, Kim JE, Sohn JH, Koh SJ, Seo JH, Lee KS, Kim SB.

Invest New Drugs. 2019 Nov 15. doi: 10.1007/s10637-019-00863-8. [Epub ahead of print]

PMID:
31728715
4.
5.

Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.

Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Shiozaki A, Fujiwara H, Konishi H, Naito Y, Teramukai S, Itoh Y.

Cancer Sci. 2019 Dec;110(12):3754-3760. doi: 10.1111/cas.14218.

6.

Hematologic Growth Factors.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2016 Aug 16.

7.

Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.

Li S, Liu J, Guo H, Gawade PL, Kim C, Bensink ME, Chandler D.

Support Care Cancer. 2019 Oct 17. doi: 10.1007/s00520-019-05080-w. [Epub ahead of print]

PMID:
31624920
8.

Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors.

Laali E, Fazli J, Sadighi S, Mohammadi M, Gholami K, Jahangard-Rafsanjani Z.

J Oncol Pharm Pract. 2019 Oct 15:1078155219875507. doi: 10.1177/1078155219875507. [Epub ahead of print]

PMID:
31615347
9.

A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).

Cabanillas F, Rivera N, Acosta M, Pardo W, Solivan P, Rivera C, Liboy I.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):776-783. doi: 10.1016/j.clml.2019.07.002. Epub 2019 Jul 17.

PMID:
31591042
10.

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.

Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR.

Clin Cancer Res. 2019 Sep 26. doi: 10.1158/1078-0432.CCR-19-1483. [Epub ahead of print]

PMID:
31558477
11.

Evolution of the EU Biosimilar Framework: Past and Future.

Wolff-Holz E, Tiitso K, Vleminckx C, Weise M.

BioDrugs. 2019 Dec;33(6):621-634. doi: 10.1007/s40259-019-00377-y. Review.

13.

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ.

Prostate. 2019 Nov;79(15):1752-1761. doi: 10.1002/pros.23899. Epub 2019 Sep 9.

PMID:
31497882
14.

Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.

Tossey JC, Reardon J, VanDeusen JB, Noonan AM, Porter K, Arango MJ.

Med Oncol. 2019 Sep 7;36(10):87. doi: 10.1007/s12032-019-1309-6.

PMID:
31494781
15.

Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report.

Takuwa H, Tsuji W, Goto T, Otsuji T, Yotsumoto F.

Mol Clin Oncol. 2019 Oct;11(4):371-375. doi: 10.3892/mco.2019.1907. Epub 2019 Aug 7.

16.

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.

McBride A, Krendyukov A, Mathieson N, Campbell K, Balu S, Natek M, MacDonald K, Abraham I.

J Med Econ. 2019 Sep 3:1-9. doi: 10.1080/13696998.2019.1658591. [Epub ahead of print]

PMID:
31433700
17.

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects.

Wessels H, Lehnick D, Höfler J, Jankowsky R, Chamberlain P, Roth K.

Pharmacol Res Perspect. 2019 Aug 13;7(5):e00507. doi: 10.1002/prp2.507. eCollection 2019 Oct.

18.

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects.

Roth K, Lehnick D, Wessels H, Höfler J, Gastl B, Jankowsky R.

Pharmacol Res Perspect. 2019 Aug 13;7(5):e00503. doi: 10.1002/prp2.503. eCollection 2019 Oct.

19.

Racial Differences in Accepting Pegfilgrastim Onpro Kit (On-Body Injector) Use Among Cancer Patients.

Saif MW, Hackenyos DW, Smith MH, Healey P, Relias V, Wasif K.

Clin Oncol (Las Vegas). 2019;1(6). pii: 1026. Epub 2019 Feb 25.

20.

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.

Weycker D, Doroff R, Hanau A, Bowers C, Belani R, Chandler D, Lonshteyn A, Bensink M, Lyman GH.

BMC Cancer. 2019 Aug 9;19(1):792. doi: 10.1186/s12885-019-6010-9.

Supplemental Content

Loading ...
Support Center